Compare PENG & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PENG | ZLAB |
|---|---|---|
| Founded | 1988 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.6B |
| IPO Year | 2017 | 2017 |
| Metric | PENG | ZLAB |
|---|---|---|
| Price | $63.85 | $25.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $27.78 | ★ $49.60 |
| AVG Volume (30 Days) | ★ 2.5M | 934.8K |
| Earning Date | 04-01-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 128.00 | 38.46 |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $1,368,794,000.00 | $460,156,000.00 |
| Revenue This Year | $14.55 | $9.75 |
| Revenue Next Year | $16.14 | $26.03 |
| P/E Ratio | $47.21 | ★ N/A |
| Revenue Growth | N/A | ★ 15.33 |
| 52 Week Low | $16.04 | $15.96 |
| 52 Week High | $89.86 | $36.77 |
| Indicator | PENG | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 54.68 | 77.92 |
| Support Level | $57.62 | $16.98 |
| Resistance Level | $75.32 | N/A |
| Average True Range (ATR) | 4.33 | 1.12 |
| MACD | 1.16 | 0.77 |
| Stochastic Oscillator | 92.47 | 92.22 |
Penguin Solutions Inc is an end-to-end technology company engaged in Intelligent Platform Solutions, Integrated Memory, and Optimized LED business. Its product include Servers, software, OCP HPC & AI system, Racks and Edge. Servers include AMD-based Serves, Intel-based Servers, etc. Software products include Scyld ClusterWare, Scyld Cloud Central, etc. OCP HPC & AI Systems includes OCP Servers & Storage and etc.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.